Could antiretrovirals be treating EBV in MS? A case report

Area of Science:

• Neurology
• Virology

Background:

• Relapsing-remitting multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Current MS treatments aim to reduce inflammation and manage symptoms, but novel therapeutic strategies are continually sought.
• The potential role of viral infections, such as Epstein-Barr virus (EBV), in MS pathogenesis is an area of ongoing research.

Observation:

• An HIV-negative individual diagnosed with relapsing-remitting MS experienced significant clinical improvement after treatment with Combivir (zidovudine/lamivudine).
• The patient reported complete resolution of persistent fatigue and paresthesiae within months of initiating therapy.
• Magnetic resonance imaging (MRI) revealed a simultaneous reduction in lesion burden correlating with clinical improvements.

Findings:

• Treatment with zidovudine/lamivudine led to sustained remission of MS symptoms for over three years.
• The observed therapeutic effect suggests a potential disease-modifying role for the antiviral properties of zidovudine.
• Zidovudine is a known inhibitor of Epstein-Barr virus (EBV) lytic DNA replication, a virus implicated in MS.

Implications:

• This case highlights the potential of antiviral therapies, specifically targeting EBV, as a novel treatment strategy for multiple sclerosis.
• Further clinical investigation into zidovudine or similar agents for MS management is warranted.
• Understanding the interplay between viral infections and autoimmune processes in MS could lead to more targeted and effective treatments.